Illegal Medical Product and Deferred Prosecution Agreement in Malaysia

Zeti Zuryani Mohd Zakuan; Siti Asishah Hassan; Anida Mahmood

doi:10.47405/mjssh.v8i2.2145

Zeti Zuryani Mohd Zakuan Department of Law, Universiti Teknologi MARA, Cawangan Perlis, Kampus Arau, 02600, Arau, Perlis, Malaysia.
Siti Asishah Hassan Department of Law, Universiti Teknologi MARA, Cawangan Perlis, Kampus Arau, 02600, Arau, Perlis, Malaysia.
Anida Mahmood Faculty of Law, Universiti Teknologi MARA, 40450 Shah Alam, Selangor, Malaysia.

DOI: https://doi.org/10.47405/mjssh.v8i2.2145

Keywords: consumer, deferred prosecution agreement, illegal medical product, product liability

Abstract

The recent covid-19 pandemic has seen a demand for medical products. The problem identified is that unscrupulous traders are seen to be taking advantage of the situation by selling illegal products. The Ministry of Health seized 23 278 illegal pharmaceutical products worth more than RM 600 000 during Operation Pangea XIII, which was conducted in 2020. One of the factors identified for such illegal activity is the prosecution and penalty imposed on the traders is ineffective in acting as a deterrent as the profits gained from selling the products are much higher than the fine imposed. Adopting a doctrinal approach, this article analyses the provisions for combatting illegal medical products in Malaysia. The article aims to assess whether the provisions successfully overcame the problems of illegal medical products on the market. It is submitted the present law is outdated. It was found that Malaysia should consider implementing DPA. This is because based on the experience of other jurisdictions, DPA is able to deter traders from selling illegal medical products by imposing hefty penalties. Thus, DPA will create healthy environments for the consumption of medical products for Malaysia consumers.

Downloads

Download data is not yet available.

References

Abdullah, N.C. (2020). Legal research methodology. Sweet & Maxwell

Abdul-Rahman, H. (2012). Beware of illegal advertisements. Ministry of Health, Malaysia. https://www.pharmacy.gov.my/v2/en/news/04-dec-2012/beware-illegal-advertisements.html.

Bakerdonelson. (2013). Deferred prosecution agreement: How effective compliance program can help you plan for the unpredictable. Bakerdonelson. https://www.bakerdonelson.com/deferred-prosecution-agreements-how-effective-compliance-program-can-help-you

Bidin, A. (2009). Counterfeit medicine: A threat to the public health and pharmaceutical industry. International Conference on Corporate Law 2009, Surabaya, Indonesia.

Brez, Z.S., Cannon, Q. B., Filip, M. Goel, A. Lable, C.A., Nemirow, K.B., Pardesi, K.B., Sharpe, R., Stuckwisch, W.J., Thompson, M., Tumani, S. & Wu. J. (2018). Singapore introduces deferred prosecution agreement. NYU. https://wp.nyu.edu/compliance_enforcement/2018/04/04/singapore-introduces-deferred-prosecution-agreements/

Bu, Q. (2021). The viability of Deferred Prosecution Agreements (DPAs) in the UK: The impact on global anti-bribery compliance. European Business Organization Law Review, 22, 173–201. https://doi.org/10.1007/s40804-021-00203-5.

Chua, E. & Qi, B.C.W. (2019). Deferred Prosecution Agreements in Singapore: What is the appropriate standard for judicial approval? International Commentary on Evidence, 16(1). https://doi.org/10.1515/ice-2019-0002.

Delaney, R. (2009). Congressional legislation: The next step for corporate deferred prosecution agreements. Marquette Law Review, 19(23), 877-904.

Fairgrieve, D., Feldschreiber, P., Howells, G., & Pilgerstorfer QC, M. (2020). Products in a Pandemic: Liability for Medical Products and the Fight against COVID-19. European Journal of Risk Regulation, 11, 565-603.

Hawley, S., King, C., & Lord, N. (2020). Justice for whom? The need for a principled approach to deferred prosecution in England and Wales. In T. Søreide, & A. Makinwa (Eds.), Negotiated settlements in bribery cases: A Principled Approach. Edward Elgar Publishing Ltd., Cheltenham.

Hickey, S.J. (2021). Remediation in foreign bribery settlements: The foundations of a new approach. Chicago Journal of International Law, 21(2). https://chicagounbound.uchicago.edu/cjil/vol21/iss2/5.

Idzam, I.H.A. & Mohammed, M. (2020). The concept of deferred prosecution agreements in the landscape of corporate liability for corruption in Malaysia – An inevitable necessity? Zulrafique. http://www.zulrafique.com.

Ismail, M. (2013). Counterfeit Medicinal Products: The Challenges and Nowadays Towards NCD. The Malaysian Experience. Ministry of Health. http://jknkelantan.moh.gov.my/khc2013/uploads/pdfs/ple01.pdf

Ismail, R, Zakuan, Z.Z.M, Yusoff, S.S.A, Isa, S.M, & Manap, N.A. (2018). Consumers’ Basic Right to Housing: The Role of Institutional Frameworks in Malaysia. International Journal of Asian Social Science, 8(8), 501-508.

Khairulrijal, R. (2020). Covid – 19: Sales of illegal medicines soar, Operation Pangea XIII. NST. https://www.nst.com.my/news/nation/2020/04/588631/covid-19-sales-illegal-medicines-soar.

Loo, S. C., Norkhair, M. I., Hsiung, T. M., Jabar, A. H. A. A. & Talin, B. A. A. (2019). Overview of prosecution against illegal drugs and cosmetics by pharmacy enforcement branch (PEB) in Sarawak Malaysia. International Journal of Research in Pharmaceutical Sciences, 10(SPL1). https://doi.org/10.26452/ijrps.v10iSPL1.1667.

Medicines & Healthcare products Regulatory Agency (MHRA). (2020). A guide to what is a medicinal product. MHRA Guidance Note 8.

Mokhtar, F. S., Ismail, R.,Salleh, A.M.M., Ariffin, Z.Z. (2016). Medical product liability in Malaysia: The need for legislative intervention. The Social Sciences, 11(21), 5162-5165.

Nortajuddin, A. (2020). Dangers of fake medical supplies in a pandemic. The ASEAN Post. http://www.theaseanpost.com/article/dangers-fake-medical-supplies-pandemic.

Ong, C., Yee, K.P. & Shuh. G.Y. (2020). Fake goods epidemic during the Covid 19 global pandemic. Skrine. https:// www.skrine.com/insights/newsletter/july-2020/fake-goods-epidemic-during-the covid-19-global-pandemic.

Sinaga, M.R. (2021). Konsep Deferred Prosecution Agreement (DPA) Dalam Upaya Pemberantasan Korupsi oleh Korporasi di Indonesia. De Lega Lata: Jurnal Ilmu Hukum, 6(1), 80-97.

Yaqin, A. (2007). Legal research and writing. LexisNexis.

Zakuan, Z.Z.M, Ismail, R.Yusoff, S.S.A,Mustafa, C.N. & Markom, R.(2013). Legal framework as a consumer protection framework. The Social Sciences, 8, 315-318.

Zakuan, Z.Z.M. and Ismail, R. (2019). Health supplement and product liability in Malaysia: A call for reform. 2019. Malaysian Journal of Consumer and Family Economics, 23(1), 33 – 55.

Zakuan, Z.Z.M., Ismail, R., Yusoff, S.S.A., Markom, R. (2015). Consumer court: Towards a better consumer protection in Malaysia. International Business Management, 9(6), 1495 – 1499.

Zakuan, Z, Z., Ismail, R., Ahmad, S.S. & Markom, R. (2014). Health institution as a consumer protection framework in Malaysia. Global Journal of Politics and Law Research, 2(3), 77-83.

Zulkifli, N.W., Aziz, N.A., Hassan, Y., Hassali, M.A., Bahari, N.L.Z, and Ahmad, A. (2016). Are we on the right track? Overview of unregistered drugs in Malaysia. Journal of Pharmacy Practice and Community Medicine, 2(4), 107-115.